Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Researchers from Mass General Brigham evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the ...

Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person's risk of stroke, heart failure and even ...

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation system in a larger group of patients with atrial fibrillation.

Symptoms that are sometimes diagnosed as part of dementia might actually be related to a treatable liver condition, according ...

Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17.

Sydney researchers have found that Levofloxacin substantially reduces risk of drug-resistant tuberculosis. This discovery offers new hope against a disease that infects more than 400,000 people ...

But just seven years ago, and despite living with HIV for nearly half his life, Duffy was remarkably healthy, working in ...

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic ...

If you take medications to treat HIV, some of those can also cause HIV rashes. Most HIV rashes aren't serious and will typically clear up in a few days to a few weeks, even without treatment.